Clinical Trial Update: Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study evaluating QL1706 in combination with chemotherapy as first-line treatment for extensive-stage small cell lung cancer has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 2 | Status: COMPLETED